Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 94,372,096
- Total 13F shares
- 101,516,641
- Share change
- -1,570,686
- Total reported value
- $58,880,322
- Put/Call ratio
- 33%
- Price per share
- $0.58
- Number of holders
- 97
- Value change
- -$4,474,635
- Number of buys
- 52
- Number of sells
- 35
Report period
Q2 2024
Institutions
97
Top holders
10
XFOR full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Top shareholders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
18%
|
16,915,784
|
$23,512,940 | — | 31 Mar 2024 | |
| NEA Management Company, LLC |
13F
|
Company |
16%
|
14,986,793
|
$20,831,642 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
9.3%
|
8,735,867
|
$12,142,855 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.3%
|
7,827,727
|
$10,880,540 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
7.6%
|
7,133,515
|
$9,915,586 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
4.9%
|
4,579,926
|
$6,366,097 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
4.5%
|
4,276,315
|
$5,944,078 | — | 31 Mar 2024 | |
| Sio Capital Management, LLC |
13F
|
Company |
3.8%
|
3,588,427
|
$4,987,914 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
3.8%
|
3,545,454
|
$4,928,181 | — | 31 Mar 2024 | |
| KINGDON CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
3.7%
|
3,473,683
|
$4,828,419 | — | 31 Mar 2024 | |
| AXA S.A. |
13F
|
Company |
3.3%
|
3,074,372
|
$4,273,377 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.1%
|
2,945,424
|
$4,094,622 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
2,523,555
|
$3,507,741 | — | 31 Mar 2024 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
2.6%
|
2,435,426
|
$3,385,242 | — | 31 Mar 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
2.6%
|
2,413,000
|
$3,354,070 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.5%
|
1,406,425
|
$1,954,932 | — | 31 Mar 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
1.4%
|
1,335,521
|
$1,856,374 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
1,058,930
|
$1,471,913 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.1%
|
1,054,488
|
$1,465,738 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.97%
|
915,000
|
$1,271,850 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.85%
|
805,359
|
$1,119,449 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.81%
|
762,854
|
$1,060,367 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.69%
|
650,000
|
$903,500 | — | 31 Mar 2024 | |
| Propel Bio Management, LLC |
13F
|
Company |
0.57%
|
535,000
|
$743,650 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.53%
|
502,665
|
$698,704 | — | 31 Mar 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.48%
|
448,708
|
$623,704 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.46%
|
438,114
|
$608,978 | — | 31 Mar 2024 | |
| Simplify Asset Management Inc. |
13F
|
Company |
0.42%
|
400,000
|
$556,000 | — | 31 Mar 2024 | |
| ROYCE & ASSOCIATES LP |
13F
|
Company |
0.36%
|
342,363
|
$475,885 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.36%
|
335,974
|
$467,004 | — | 31 Mar 2024 | |
| New Leaf Venture Partners, L.L.C. |
13F
|
Company |
0.35%
|
335,000
|
$465,650 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.34%
|
323,843
|
$450,142 | — | 31 Mar 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.34%
|
321,021
|
$446,000 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.27%
|
258,759
|
$359,675 | — | 31 Mar 2024 | |
| David M. Knott Jr. |
13F
|
Individual |
0.19%
|
180,993
|
$252,000 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.17%
|
163,415
|
$227,135 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.14%
|
129,084
|
$179,427 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.13%
|
127,051
|
$176,601 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.11%
|
102,712
|
$142,769 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.1%
|
98,622
|
$137,085 | — | 31 Mar 2024 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.09%
|
86,225
|
$119,855 | — | 31 Mar 2024 | |
| Amundi |
13F
|
Individual |
0.09%
|
81,305
|
$97,566 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.08%
|
77,452
|
$107,657 | — | 31 Mar 2024 | |
| Lighthouse Investment Partners, LLC |
13F
|
Company |
0.07%
|
70,422
|
$97,887 | — | 31 Mar 2024 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.07%
|
61,735
|
$85,812 | — | 31 Mar 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.07%
|
61,575
|
$85,589 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.06%
|
55,296
|
$76,861 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.06%
|
52,789
|
$73,376 | — | 31 Mar 2024 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.05%
|
51,551
|
$71,656 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.05%
|
51,127
|
$71,066 | — | 31 Mar 2024 |
Institutional Holders of X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR) as of Q2 2024
As of 30 Jun 2024,
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR) was held by
97 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
101,516,641 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, NEA Management Company, LLC, BlackRock Inc., VANGUARD GROUP INC, ORBIMED ADVISORS LLC, KINGDON CAPITAL MANAGEMENT, L.L.C., ADAGE CAPITAL PARTNERS GP, L.L.C., Soleus Capital Management, L.P., PERCEPTIVE ADVISORS LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
97
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
96
Q2 2024 holders
97
Holder diff
1
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.